Lineage Cell Therapeutics (LCTX) 10-K/A 2017 FY Annual report (amended)

Exhibit 31

CERTIFICATIONS

I, Michael D. West, certify that:

1.	I have reviewed this annual report on Form 10-K/A of BioTime, Inc.
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Date: April 2, 2018

/s/ Michael D. West  

Michael D. West  

Co-Chief Executive Officer  

Exhibit 31

CERTIFICATIONS

I, Aditya Mohanty, certify that:

1.	I have reviewed this annual report on Form 10-K/A of BioTime, Inc.
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Date: April 2, 2018

/s/ Aditya Mohanty 

Aditya Mohanty  

Co-Chief Executive Officer  

Exhibit 31

CERTIFICATIONS

I, Russell Skibsted, certify that:

1.	I have reviewed this annual report on Form 10-K/A of BioTime, Inc.
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Date: April 2, 2018

/s/ Russell Skibsted

Russell Skibsted  

Chief Financial Officer